# Evaluating the Safety and Immunogenicity of HIV Clade C DNA Vaccine and MF59- or AS01B-Adjuvanted Clade C Env Protein Vaccines in Various Combinations in Healthy, HIV-Uninfected Adults

> **NCT02915016** · PHASE1,PHASE2 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 334 (actual)

## Conditions studied

- HIV Infections

## Interventions

- **BIOLOGICAL:** DNA-HIV-PT123 vaccine
- **BIOLOGICAL:** Bivalent Subtype C gp120/MF59 vaccine
- **BIOLOGICAL:** Bivalent Subtype C gp120/AS01B vaccine
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT02915016
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-12-07
- **Primary completion:** 2019-08-07
- **Final completion:** 2020-02-12
- **Target enrollment:** 334 (ACTUAL)
- **Last updated:** 2022-04-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02915016

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02915016, "Evaluating the Safety and Immunogenicity of HIV Clade C DNA Vaccine and MF59- or AS01B-Adjuvanted Clade C Env Protein Vaccines in Various Combinations in Healthy, HIV-Uninfected Adults". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02915016. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*